Evidence map›Paper›PMID 39461990›Full record

ArticleScientific reports2024

Mechanistic insights into the interaction of anxiolytic drugs with human serum albumin in a ternary system utilizing spectroscopic and molecular modeling approaches.

Elaheh Jalali, Javad Sargolzaei, Parisa Rajabi

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Ultrabright NIR-II Nanoprobes forACS nanoscience Au · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Elaheh JalaliDepartment of Biology, Faculty of Science, Arak University, Arak, Iran.
Javad SargolzaeiDepartment of Biology, Faculty of Science, Arak University, Arak, Iran. j-sargolzaei@araku.ac.ir.ORCID 0000-0001-5366-2014
Parisa RajabiDepartment of Psychiatry, Arak University of Medical Sciences, Arak, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, buspirone has been co-administered with sertraline to resolve sexual disorders caused by sertraline. Therefore, the present study was conducted to investigate the interaction effect of two antidepressants and anxiolytic drugs, sertraline and buspirone, on human serum albumin (HSA) using spectroscopic and molecular docking techniques. Fluorescence emission spectroscopy and molecular docking were used to calculate the binding affinity and determine the best binding sites for these two drugs. Additionally, UV-visible and circular dichroism spectroscopy were performed to investigate the effect of these drugs on the conformational changes of HSA. The results showed that both drugs have a strong ability to quench the fluorescence of HSA through a static mechanism, and cause structural changes in HSA. It was also found that binding of sertraline and buspirone to HSA is spontaneous (ΔG° <) and hydrophobic interactions, van der Waals forces and hydrogen bonds play a significant role in these interactions in the ternary system. In addition, molecular docking data showed that both drugs bind with high affinity to the Trp residue in subdomain IIA. The binding constants (K

Indexed as

Anti-Anxiety AgentsMolecular Docking SimulationProtein BindingSertralineSerum Albumin, HumanBinding SitesBuspironeCircular DichroismHumansHydrogen BondingHydrophobic and Hydrophilic InteractionsSpectrometry, FluorescenceThermodynamicsAnti-Anxiety AgentsBuspironeSertralineSerum Albumin, HumanBuspironeHuman serum albuminInteractionMolecular dockingSertralineSpectroscopy

Identifiers

PMID39461990
PMCPMC11513042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.